GLP‑1 weight‑loss treatments are becoming more prominent in India as obesity and type‑2 diabetes rates rise. Drugs like Mounjaro (tirzepatide) and Wegovy (semaglutide) are now approved for weight management under certain conditions — for example for people with BMI ≥ 30, or ≥ 27 with comorbid health issues.